Table 2. Analyses of demographic, clinical, pathologic and perioperative characteristics, and oncologic control comparison.

Characteristics	No. of studies	No. of patients, BNP/control	OR/WMD (95% CI)	P-Value	Study heterogeneity				Egger test (P-Value)
					Chi2	df	P-Value	I2
Age, year	10	1014/898	−1.38 [−2.82, 0.05] a	0.06	82.98	9	<0.00001	89%	0.103
PSA, ng/ml	7	722/618	0.14 [−0.08, 0.36] a	0.20	10.86	6	0.09	45%	0.084
Prostate volume, ml	5	642/537	−2.24 [−4.27, −0.22] a	0.03	0.34	4	0.99	0%	0.519
Clinical stage
Organ confined ≤ cT2	7	698/636	1.68 [0.61, 4.60]	0.31	1.59	1	0.21	37%	-
Non-organ confined ≥ cT3	7	698/636	0.60 [0.22, 1.63]	0.31	1.59	1	0.21	37%	-
Pathologic stage
Organ confined ≤ pT2	6	776/687	1.02 [0.80, 1.32]	0.85	1.84	5	0.87	0%	0.678
Non-organ confined ≥ pT3	6	776/687	0.98 [0.76, 1.27]	0.88	0.97	5	0.97	0%	0.736
Biopsy Gleason score b	5	233/368	−0.39 [−0.92, 0.13] a	0.14	32.15	4	<0.00001	88%	0.031
Biopsy Gleason score
≤ 7	2	382/309	1.33 [0.72, 2.44]	0.36	0.73	1	0.39	0%	-
> 7	2	382/309	0.75 [0.41, 1.38]	0.36	0.73	1	0.39	0%	-
Pathologic Gleason score
≤ 7	4	633/516	1.29 [0.90, 1.83]	0.16	1.54	3	0.67	0%	0.862
> 7	4	633/516	0.78 [0.54, 1.12]	0.17	1.61	3	0.66	0%	0.763
Operation time, min	4	591/485	−7.54 [−30.80, 15.73] a	0.53	58.41	3	<0.00001	95%	0.130
EBL, ml	5	621/515	1.10 [−40.70, 42.89] a	0.96	24.87	4	<0.0001	84%	0.472
Catheterization, day	3	532/399	−0.16 [−0.58, 0.27] a	0.47	0.75	2	0.69	0%	0.663
PSM	13	1130/1155	1.04 [0.81, 1.34]	0.74	9.11	11	0.61	0%	0.634
Biochemical failure	5	276/300	0.78 [0.49, 1.22]	0.27	3.50	4	0.48	0%	0.643

CI = confidence interval; OR = odds ratio; WMD = weighted mean difference; PSM = positive surgical margin

^*Statistically significant results are shown in bold.

^aValues of WMD

^bBiopsy Gleason score (continuous)